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The Rare Anaemias
Joan-Lluis Vives-Corrons
Abstract
Anaemia is a common worldwide disorder mainly due to iron or vitamins
deficiency. However, among the rare diseases (RD), there is a group associated with
anaemia as main clinical manifestation or rare anaemias (RA). RA are mostly heredi-
tary, and since they are little known, even for professionals, they remain undiagnosed,
or misdiagnosed, for very long periods of time. This creates in patients, or, in their
parents (if they are children) a permanent situation of stress due to the absence of a
diagnosis, the impossibility to predict the course of the disease, and to the impossibil-
ity to perform, genetic counselling for future pregnancies. About 83 different RA have
been described and their mechanism is in general a bone marrow or a red blood cell
(RBC) defect. The most well-known RA are Fanconi anaemia, the thalassemia syn-
dromes, sickle cell disease, hereditary haemolytic anaemias and paroxysmal nocturnal
haemoglobinuria (PNH). The main objective of this chapter is to offer a review of the
state of the art of RA knowledge and a way to facilitate their identification and final
diagnosis through clinical manifestations and laboratory diagnostic tests.
Keywords: anaemia, red blood cell erythropoiesis, haemoglobin, haemolysis,
haemoglobins, enzymes, membrane
1. Introduction
Anaemia is very common condition in human pathology that may result from a
wide variety of causes, either congenital or acquired. It is always the manifestation
of an underlying disease, and never a disease by itself. Haemoglobin concentration
(Hb) is the most reliable indicator of anaemia, but since its normal distribution at
population level varies with age, sex, and physiological status, the Word Health
Organization (WHO) has defined the existence of anaemia when Hb is less than
110 g/L in children and pregnant women, 120 g/L in non-pregnant women and
130 g/L in men. Moreover, measuring Hb is relatively easy and inexpensive, and
currently, all automated and semi-automated haematology analysers measure Hb
with great precision and accuracy. It is well known that iron deficiency in children
and women and chronic diseases in adults and elderly, is the most frequent cause
of mild to moderate anaemia worldwide [1, 2].
In general, there are three primary causes of anaemia: (1) Bone marrow eryth-
ropoietic defects associated with or without reduced haemoglobin synthesis.
(2) Haemolysis or excessive destruction of mature red blood cells (RBCs), and
(3) blood loss or bleeding. Anaemia can be the consequence of a single disease (e.g.
haemoglobinopathy, enzyme deficiency, etc.), but it can be also the expression of
external factors such as nutritional deficiencies, parasitic or viral infection, and
other. However, there is a group of anaemias that is considered rare because their
frequency in our population is less than 5 cases for 10,000 individuals. These are the
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so-called rare anaemias (RA), mostly of congenital origin [3]. RA are an important,
and relatively homogeneous group of rare diseases (RD), where anaemia is the first
and most relevant clinical manifestation of the disease. This importance was recog-
nized, for first time, by the European Commission (EC) that in 2002 approved the
co-financing of the DG-SANCO Project: “European Network for rare and congenital
diseases” (ENERCA; www.enerca.org). Interestingly, this Project started shortly
before the creation of the High Level Group (HLG) in 2004 that brought together
experts from all the Member States (MS) in several areas of RD expertise. For RA,
this was a great advantage, because it facilitated the progressive development of
ENERCA Project in parallel to the development of the different HLG areas of action:
(a) Patient safety and quality of care, (b) Health impact assessment and health
systems, (c) Health technology assessment, (d) European workforce for health
professionals, e) European reference networks, (f) Information and e-health and
more recently, (g) Cross-border healthcare purchasing and provision [4].
Before ENERCA, RA were almost unknown in Europe, including some health
professionals, because in many cases, the cause of the anaemia was not known and/
or there is no treatment available. Moreover, for many years, anaemias, in general,
have been underestimated by public health providers, due to its frequent
misdiagnosis with iron deficiency anaemia, the most frequent cause of anaemia
worldwide. ENERCA changed definitively this situation by developing three
consecutive phases with a total duration of 15 years (www.enerca.org). The first
ENERCA Project (ENERCA 1), starting in 2003, dedicated to congenital RA, only,
allowed the establishment of the necessary background for a sustainable coordina-
tion in the area of health information, collection of epidemiological data,
comparability issues, exchange of data and information within and between MS. At
this time, it also facilitated a rapid reaction to RA diagnosis and treatment. The
second ENERCA Project (ENERCA 2) starting in 2005, covered, in addition, to
congenital anaemias, other rare causes of anaemia, either hereditary or acquired,
and dedicated more and stronger activities to health Information, patient’s data
collection, education and training and quality assessment for special RA diagnostic
procedures. This has provided a first and unique approach for prevention, diagnosis
and treatment of RA in the word. The third ENERCA Project (ENERCA 3), starting
in 2009, was co-financed by the EC through its Executive Agency for Health and
Consumers (EAHC) and its objectives were parallel to the strategic objectives of the
EU Health Programme 2008–2013 consistent in the creation of a European Reference
Network (ERN) of Centres of Expertise (CEs) in Rare Anaemias (Figure 1).
After 2013, the EC has approved co-financing ENERCA Project for an additional
3 years period (2014–2016), with the aim of developing and implementing the new
e-health information and communication technologies (ICT) for assuring the same
access to health services in RAs across Europe, independently from the place of
residence. This new and last, but not least, ENERCA Project, called e-ENERCA, was
based, in part, on previous ENERCA projects achievements, but adapted to the
Directive 2011/24/EU of 9 March 2011 on the application of patients’ rights in cross-
border healthcare has become a very important tool for the promotion of Rare
Diseases (RD) European Reference Networks (ERN) that, within that general
framework, have provided the following benefits:
• Access to experts and expertise throughout the European MS for both patients
and health professionals, independently of the country of origin or practice,
reduce inequalities and maximize the cost-effective use of resources;
• Epidemiological surveillance throughout EU by gathering comparable data on
patients affected by RAs and allowing the implementation of preventive
programmes for tackling RAs;
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• Fostering of best practices for prevention, diagnosis and clinical management;
• Promotion of knowledge dissemination of share of expertise and support of
research, and increase awareness about RAs;
• Facilitate the transposition of the Directive 2011/24/EU of 9 March 2011 on the
application of patients’ rights in cross-border healthcare.
For maintaining its sustainability, in March 2016, ENERCA applied for the ERN
European Commission (EC) Call, by expanding the rare anaemias to all the other
rare haematological diseases (RHD), including oncological and non-oncological
diseases [5].
Figure 1.
European Network for Rare and Congenital Anaemias Map.
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Currently, the ERN for Rare Haematological Diseases (RHD), called
EuroBloodNet (www.eurobloodnet.eu), is one of the 24 recognized ERNs, and after
its second year of life, can be considered an acceptable tool for the improvement
RHD diagnosis and for the provision of high-quality healthcare to all patients who
have conditions requiring a particular concentration of resources or expertise. In
brief, EuroBloodNet will also provide focal points for medical training and research,
information dissemination and evaluation, and will contribute to the establishment
of national contact points for RHD. Up to now, however, only 66 Centres in Europe
are recognized as Health Care Providers (HCP) for RHD, a situation created by the
extremely different endorsement decisions of individual Members States (MS). So,
we have arrived to the astonishing situation in that many of the ENERCA experts,
well recognized by the state of the art and ENERCAWhite Book recommendations,
are not included as EuroBloodNet experts because they do not belong to an national
recognized Healthcare Provider (HCP) and cannot take participate in the Network
activities and/or take profit from their advantages. In order to overcome this
restraint, a new EC call for membership application to the existing European
Reference Networks (ERNs) has been launched on September 30, 2019.
Hereditary (>80%)
Erythropoietic defects (non-regenerative anaemias)
• Fanconi anaemia (FA)
• Diamond-Blackfan anaemia (DBA)
• Congenital dyserytropoietic anaemia (CDA)
RBC defects (regenerative anaemias)
• Thalassaemia syndromes (Cooley anaemia)
• Sickle-cell disease (SCD)
• Hereditary membranopathies
◦ Hereditary spherocytosis (HS)
◦ Hereditary elliptocytosis (HE)
◦ Hereditary stomatocytosis (HSt)
• Erythroenzymopathies
◦ Glucose-6-phosphate dehydrogenase deficiency (Favism)
◦ Pyruvate kinase deficiency (PKD)
◦ Ultra-rare erythroenzymopathies associated with or without muscular or neurological disease
Iron metabolism defects (non-regenerative anaemias)
• Congenital sideroblastic anaemia (CSA)
• Non-sideroblastic anaemias with microcytosis (IRIDA)*
Acquired (<20%)
Erythropoietic defects (non-regenerative anaemias)
• Bone marrow aplasia (BMA)
• Pure red cell aplasia (PRCA)
• Myelodysplastic syndromes (MDS)
RBC defects (regenerative anaemia)
• Paroxysmal nocturnal hemogobinuria (HPN)
Blood plasma abnormalities (regenerative anaemias)
• Autoimmune haemolytic anaemia (AIHA)
Microcirculation defects (regenerative anaemias)
• Haemolytic uremic syndrome (HUS)
*Iron refractory iron deficiency anaemia.
Table 1.
General classification of rare anaemias.
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2. Classification
The RA are classified into two main groups: Hereditary and acquired, and in these
groups, the mechanism of the anaemia can be sub classified into five different defects:
(1) bone marrow (erythropoietic), (2) peripheral blood (red blood cell), (3) iron
metabolism (sideroblastic and non-sideroblastic), (4) blood plasma (autoimmune
haemolytic anaemia and related syndromes) and (5) microcirculation (haemolytic
uremic syndrome and other microangiopathic disorders). This means that all RA are
the consequence of haematopoietic system defects leading to a low RBC production
(erythropoietic defects), or of RBC defects, either intrinsic or associated to plasma or
microcirculation disorders, leading to low RBC survival or haemolysis (Table 1).
ENERCA is actively contributing to the WHO Update Platform ICD-10 of
blood and blood forming organs. In this platform, anaemias, are classified into three
main groups: D50-D53 (nutritional anaemias), D54-D59 (haemolytic anaemias), and
D60-D64 (aplastic and other anaemias). This ICD classification includes all kind of
anaemias, hereditary, acquired, common and rare, and ENERCA has extracted the RA
group that has been individually listed in the ENERCAWeb page (www.enerca.org).
For practical purposes, according to their mechanism, prevalence and/or rele-
vant clinical and/or social impact in the European population, ENERCA has classi-
fied the Rare Anaemias into 10 different groups [6]:
Group 1. Haemoglobin disorders: Haemoglobinopathies and Thalassaemias.
Group 2. Hereditary Haemolytic Anaemias (HHA): Red blood cell
enzymopathies and membrane defects.
Group 3. Hereditary erythropoietic failure or aplasia: Diamond-Blackfan
anaemia (DBA) and Fanconi anaemia (FA),
Group 4. Congenital dyserythropoietic anaemias (CDA),
Group 5. Hereditary sideroblastic anaemias,
Group 6. Hereditary non-sideroblastic anaemias due to iron metabolism defects,
Group 7: Hereditary disorders of folic acid and cobalamin defects.
Group 8: Paroxysmal nocturnal haemoglobinuria (PNH),
Group 9: Anaemias due to rare complex mechanisms and.
Group 10: Anaemias of unknown origin (AUO).
The underlying cause of rare anaemias remains still unexplained in about 20% of
patients, almost one third of which might be accounted for myelodysplastic syn-
dromes. AUO can be also due to complex clinical situations and multifactorial
mechanisms, in general associated with systemic, non-haematological, hereditary or
acquired diseases. Their existence is a very important tackling exercise for clinical
and biological research.
3. Diagnostic approach
More than 80% of RA are hereditary and, therefore, have no curative treatment,
exception made of palliative therapies such as blood transfusions or erythropoietic
stimulating drugs (Erythropoietin). In clinical practice they may be some confusion
between RA and the anaemias that appear in the course of non-haematological or
systemic diseases, also called secondary anaemias. This confusion is due to the fact
that anaemia is not a disease, but a clinical manifestation, and some Rare Diseases
(RD) are associated with anaemia, moderate or severe. One example of this is the
Rendu-Osler disease (hereditary telangiectasia), a relatively well known RD where
anaemia, due to iron deficiency, is very common, and sometimes the first clinical
manifestation of the disease. Furthermore, the anaemias due to rare chronic
inflammatory diseases, vitamin deficiencies, immune diseases, malignancy, or other
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rare disorders, may probably be also considered RA, although they have not yet
been included in this group.
Hereditary RA, as in other RD, the low number of patients creates the need to
mobilize resources and their study can be efficient only if done in a coordinated
European scene of action level. Among hereditary anaemias, haemoglobinopathies
are the commonest genetic defect worldwide with an estimated 269 million carriers
[7]. They are the consequence of mutations in the globin genes, which are respon-
sible for the synthesis of haemoglobin, the main component of RBCs. These muta-
tions are leading to abnormal proteins (haemoglobin variants) or to a decreased
synthesis of globin chains (thalassaemias). In Europe, certain populations are par-
ticularly at risk of having a haemoglobinopathy. In Southern countries, their prev-
alence is higher than in central or northern Europe, but in all cases the prevalence is
less than 1 per 2000 individuals. For this reason, in Europe, haemoglobinopathies
and thalassaemias are considered a particular group of RD or RA. Whereas thalas-
saemia syndromes are inherent in the autochthonous European at risk groups
(Mediterranean anaemia), other haemoglobinopathies have been imported by
migration (Sickle-cell anaemia).
In general, the diagnosis of a RA is often prompted by pallor, noticed by the
patient, the family, and/or the General Practitioner (GP). Severity of clinical man-
ifestations is directly proportional to the acuteness of onset, and many patients do
not notice any symptoms when anaemia occurs insidiously. At the laboratory level,
the diagnosis of anaemia includes two main steps:
3.1 General diagnostic tests
General diagnostic tests always include a Complete Blood Count (CBC), the retic-
ulocyte count and the peripheral blood cell morphology examination. The CBC
includes four main parameters: (a) haemoglobin concentration (Hb), the key for
anaemia diagnosis, (b) RBC count or concentration of RBCs, given as number of cells
per litre of blood, (c) haematocrit or packed cell volume (PCV), given as the per-
centage of blood by volume that is occupied by the RBCs and (d) RBC indices or
calculations derived from (a), (b), and (c), of great help for the diagnosis and
classification of anaemias. These indices are automatically measured by modern
haematology full automated or semi-automated, analysers, and are mainly three:
(1) the mean corpuscular volume (MCV) or average size of the RBCs expressed in
femtolitres (fl), (2) the mean corpuscular haemoglobin (MCH) or average amount of
haemoglobin inside a single RBC expressed in picograms (pg) and (3) the mean
corpuscular haemoglobin concentration (MCHC) or average concentration of
haemoglobin in the RBC expressed as a percent. Sometimes the RBC distribution
width (RDW), a measure of the variation of RBC size, can be also used for anaemia
classification. Usually RBCs have a standard size of about 6–8 μm, but in certain
disorders, a significant variation in RBC size can be present. Here the RDW value is a
relatively good indicator of RBC size heterogeneity. RDW is especially useful to
differentiate iron deficiency (increased value) from thalassemia (normal value).
Reticulocyte count or number of circulating young RBCs (reticulocytes) is an impor-
tant complementary test which indicates the bone marrow capacity to overcome the
severity of anaemia [8]. Accordingly, anaemias due to RBC destruction (haemolysis)
are characterized by increased reticulocyte count (regenerative anaemias), whereas
anaemias due to erythropoietic insufficiency (aplasia or dyserythropoiesis) are char-
acterized by a lower than expected reticulocyte count from the severity of the anae-
mia (Non-regenerative anaemias). In thalassaemias, where erythropoietic insufficiency
coexists with some degree of haemolysis, the reticulocyte count may be variable.
The reticulocyte count and MCV are, up to now, the most useful criteria for
anaemia classification. According to MCV, anaemias are classified into microcytic
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(low MCV), macrocytic (high MCV) and normocytic (normal MCV). The two main
causes of microcytic anaemias are iron deficiency and thalassaemia and the two
main causes of macrocytic anaemias are cobalamin (vitamin B12) and folic acid
deficiencies. Normocytic anaemias can be due to several different causes, not
related with nutritional defects or thalassaemia, being the most frequent haemolysis
and erythropoietic failure. Here, the reticulocyte count is the most useful test to
differentiate these two conditions. In clinical practice, the most frequent cause of
anaemia is iron deficiency (ID), characterized by a low MCV (microcytic anaemia).
In southern Europe countries with higher “at risk” thalassaemia population (Medi-
terranean basin), this hereditary disorder can be misdiagnosed as iron deficiency
anaemia (IDA) because of the low MCV (<82 fL) or microcytosis. Accordingly, in a
patient with microcytosis the first step is always to exclude ID. If present, iron
supplementation has to be given until the MCV recovers its normal value. However,
if after treatment, the MCV remains low, the coexistence of a thalassemic gene has
to be investigated. It should be mentioned that there are a number of conditions
where the MCV can falsely rose masking the main clue of thalassaemia diagnosis.
This is the case in some patients with thalassaemia who co-inherit another cause of
haemolytic anaemia leading to an increased reticulocyte count. This can falsely
increase the value of MCV and masking the diagnosis of thalassemia if only the
MCV is used for initial screening.
As part of the CBC, the blood film examination is sometimes very useful because
it may provide a clue to the diagnosis of a particular RBC defect [9]. Despite the
advances in automated blood cell counting, the blood film examination retains a
crucial role in the diagnosis of RBC disorders. This is particularly important in
haemolytic anaemias and in the differential diagnosis of macrocytic anaemias. RBC
morphology examination provides in some cases (e.g. red blood cell membrane
disorders, sickle-cell anaemia), a definitive diagnosis, but, more often, it suggests a
differential diagnosis that indicates further study. Morphological changes such as
basophilic stippling and target cells in the blood film are not definitively associated
with a haemoglobinopathy, but would be helpful findings in patients with moderate
or severe anaemia associated with low MCV (Thalassaemia intermedia, or Thalas-
saemia major). Finally, RBC morphology examination has also the advantage of
speed that may be important in severe anaemias such as those mentioned before.
3.2 Cause-oriented specific diagnostic tests
These tests are the next step for the identification of the cause of the anaemia or
of its mechanism. They include a group of laboratory procedures depending on
clinical or laboratory diagnostic orientation of the anaemia [8] and, when necessary,
a final genetic identification of the cause of the disease [10]. In order to provide a
first approach to the cause of the anaemia, several diagnosis oriented flowcharts can
be found in the literature, mainly based on the morphological classification of the
anaemia (microcytic, macrocytic and normocytic).
ENERCA website (www.enerca.org) provides practical flowcharts for the diag-
nostic orientation of anaemia. For this, three patient’s data have to be provided: sex,
Hb and MCV. If anaemia is detected, one of the three available flowcharts will
appear, depending on the MCV value: low (microcytic anaemia), high (macrocytic
anaemia) and normal (normocytic anaemia). These flowcharts are not exhaustive
and the final diagnosis always requires the advice of a health professional, but they
provide the basic information on how the investigation of anaemia causes can be
undertaken in routine clinical practice. Using these flowcharts the most frequent
RAs (haemoglobinopathies, thalassaemias and haemolytic anaemias) can be easily
recognized. Depending on the results of the recommended basic tests, more specific
tests (including molecular biology) can be performed. Some of these specific tests
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can also be performed in general haematology laboratories but other tests require to
be undertaken in specialized laboratories. In all the cases External Quality Assess-
ment Schemes (EQAS) are necessary for assessing the quality of practice or for
obtaining a technical qualification. Since the most specific tests are performed in
few specialized laboratories, local (national or regional) EQAS organizations cannot
establish a specific EQAS for these procedures due to its high cost. Accordingly, the
EQAS for these procedures have to be promoted at European level as ENERCA 3 has
done with some rare diagnostic tests for RA such as Pyruvate-kinase deficiency
(PKD).
4. Rare Anaemias due to bone marrow defects
Bone marrow failure syndromes (BMFS) are multisystem diseases that are char-
acterized by varying degrees of deficiency in the production of haematopoietic
cells, which can range from the depletion of a single cell lineage (cytopenia) to that
of multiple lineages or even of all lineages (pancytopenia). The most well-known
acquired BMFS is aplastic anaemia (AA).This causes a deficiency of all three blood
cell types (pancytopenia): red blood cells (anaemia), white blood cells (leukopenia),
and platelets (thrombocytopenia) and aplastic refers to the inability of stem cells to
generate mature blood cells. It is more frequent in people in their teens and
twenties, but is also common among the elderly [11]. It can be caused by heredity,
immune disease, or exposure to chemicals, drugs, or radiation. However, in about
half the cases, the cause is unknown. The definitive diagnosis is by bone marrow
biopsy; normal bone marrow has 30–70% blood stem cells, but in aplastic anaemia,
these cells are mostly gone and replaced by fat. First line treatment for aplastic
anaemia consists of immunosuppressive drugs, typically either anti-lymphocyte
globulin or anti-thymocyte globulin, combined with corticosteroids and cyclospor-
ine. Haematopoietic stem cell transplantation is also used, especially for patients
under 30 years of age with a related matched marrow donor [11]. Congenital BMFS
are, as AA, multisystem diseases characterized by varying degrees of deficiency in
the production of haematopoietic cells, which can range from the depletion of a
single cell lineage (cytopenia) to that of multiple lineages or even of all lineages
(pancytopenia). In general they are monogenic diseases with high genetic hetero-
geneity and phenotypic overlapping, so a bone marrow and genetic analysis is
required to reach a correct diagnosis [12]. They are ultra-rare diseases with a usual
presentation during childhood and with an incidence of one to two cases per one
million individuals. In almost all cases they are associated with morbidity and
mortality, requiring lifelong blood transfusions, treatment of infections, growth
factors and transplantation of haematopoietic progenitors. Likewise, they present a
high risk of developing haematologic cancer or solid tumours and a high toxicity to
treatment, which leads to a lower life expectancy. The most relevant aspects of
some of these syndromes are the following:
4.1 Fanconi anaemia (FA)
FA (OMIM 227650) is a hereditary disease with a predominantly autosomal
recessive pattern and in one case linked to chromosome X. Its prevalence in the
general population is estimated at two to five cases per one million individuals, with
an estimated incidence of 1/131,000 births. 21 different gene mutations have been
identified so far to be a cause of congenital aplasia [13]. In most cases, each of the
parents carries one of the pathogenic variants, with three exceptions: male patients
of the FA-B subtype (FANCB gene), patients of the FA-R subtype (RAD51 gene),
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and the cases in which one of the two variants is de novo (not present in the parents
or present in only some of the gametes of one of the parents). The gene FANCB is a
gene linked to the X chromosome, so that women are asymptomatic carriers of the
pathogenic variant. From the clinical point of view, FA is considered as a syndrome
of chromosomal instability with a high spectrum of clinical manifestations that can
be grouped into congenital malformations, endocrine dysfunction, haematological
abnormalities such as severe cytopenias, myelodysplastic syndrome (MDS) or acute
myeloid leukaemia (AML) Moreover, a predisposition to develop tumours and
chromosomal fragility has been noted and in about 30% of the patients do not
present congenital malformations and are only diagnosed at the time when the
disease debuts with the haematological abnormalities [13]. To make a diagnosis, it is
necessary to confirm the chromosomal fragility by cytogenetics [14] and until a few
years ago, genetic testing was not part of the routine clinical analysis of AF patients,
partly because it was considered sufficient with the cytogenetic confirmation of the
diagnosis (chromosomal fragility) and the subtype of the patient, and on the other
hand, because the mutational analysis was boring. However, with the implementa-
tion of new high-throughput sequencing technologies [15], subtyping and muta-
tional study are now achieved at the same time, sequencing all AF genes in the same
assay, and even identifying new genes involved (Table 2). However, this approach
FA Subtype FA mutated Gen Chromosome location Protein
A FANCA 16q24.3 FANCA
B FANCB Xp22.31 FANCB
C FANCC 9q22.3 FANCC
D1 FANCD1/BRCA2* 13q12.13 BRCA2
D2 FANCD2 3p25.3 FANCD2
E FANCE 6p21–22 FANCE
F FANCF 11p15 FANCF
G FANCG 9p13 FANCG
I FANCI 15q25-26 FANCI
J FANCJ/BRIP1* 17q22-24 BRIP1
L FANCL 2p16.1 FANCL
M FANCM 14q21.3 FANCM
N FANCN/PALB2* 16p12.2 PALB2
O FANCO/RAD51C* 17q25.1 RAD51C
P FANCP/SLX4 16p13.3 SLX4
Q FANCQ/ERCC4 16q24.3 XPF
R FANCR/RAD51 15q15.1 RAD51
S FANCS/BRCA1 17q21.31 BRCA1
T FANCT/UBE2T 7q36.1 UBE2T
U FANCU/XRCC2 7q36.1 XRCC2
V FANCV/REV7 1p36.22 MAD2L2
W FANCW/RFWD3 16q23.1 FANCW
*Gene defects that predispose to the development of cancer in FA carriers.
Table 2.
Genetic subtypes and genes which mutation are implicated in the development of Fanconi anaemia.
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can cause errors in these patients, due to the broad mutational spectrum of the
disease and because all the genes related to the disease have not yet been described.
For this reason, it is advisable to always start the diagnosis by the mutational study
in patients with a positive chromosomal fragility for AF. With regard to treatment,
in addition to correcting, as far as possible, some of the congenital malformations, it
is essential to carry out a haematological follow-up in order to identify early signs
and symptoms of bone marrow (BM) failure. Current guidelines recommend
tracking blood counts every three to four months, and an annual bone marrow
aspirate. Treatment should be initiated depending on the patient’s clinical commit-
ment and continue with it in accordance with the response to it. Support measures
include transfusions of red blood cells or platelet concentrates, or the use of colony /
cytokine stimulating factors. Currently, the only curative treatment for bone mar-
row failure in these patients is the allogeneic haematopoietic stem cell transplant
(HSCT) from suitable donors. Finally, the correct and early diagnosis of AF does
not only allow the discarding of other diseases, but fundamentally enables the
proper management of their haematological alterations and genetic counselling to
the individual and his family in case of successive pregnancies. In addition, in
families with mutations in genes predisposing to cancer, it allows adequate moni-
toring and risk assessment in family members.
4.2 Diamond-Blackfan anaemia (DBA)
DBA (OMIM 105650), is a rare disease with a dominant autosomal inheritance
pattern. No differences were observed between men and women (ratio 1:1) and the
short stature is the most frequent anomaly followed by alterations in the thumb.
Other less frequent anomalies have been described, such as craniofacial alterations,
cleft lip, cleft palate and short neck. In DBA, the first description was a pure neonatal
anaemia that required transfusion support. At present, about 1000 cases have already
been described in the literature, and approximately 25% of them have at least one
congenital anomaly. The average age for diagnosis is 3 months, ranging from birth to
64 years of age, with 98% of cases diagnosed in the first year of life. DBA has its
molecular basis in heterozygous mutations in the genes encoding the components of
either the small 40S or the large 60S ribosomal subunits that affect the processing of
ribosomal RNA. Recently, DBA has also been related to mutations in the GATA-1
DBS Subtypes % of patients Locus Mutated Gene Protein
AD 25 19q13.2 RPS19 RPS19
AD 2 10q22–23 RPS24 RPS24
AD 1 15q25.2 RPS17 RPS17
AD 7 1p22.1 RPL5 RPL5
AD 5 1p36.11 RPL11 RPL11
AD 3 3q29 RPL35A RPL35A
AD 1 2p25.3 RPS7 RPS7
AD 7 6p21.31 RPS10 RPS10
AD 3 12q13 RPS26 RPS26
AD <1 17p13.1 RPL26 RPL26
AD <1 14q21.3 RPS29 RPS29
AD <1 18q21.1 RPL17 RPL17
AD <1 3p24.2 RPL15 RPL15
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transcription factor [16], but about 45% of patients with ADB lack mutations in these
identified genes, as shown in Table 3. It is likely that the genetic defects in this
pathology accelerate the apoptosis of erythroid progenitor cells, since it has been
shown that MDM2, a central regulator of p53, that acts as a ubiquitin ligase that leads
to the degradation of p53, binds specifically to several free ribosomal proteins. From
the clinical point of view, the diagnosis of DBA is complex. Blood counts generally
show a macrocytic anaemia with reticulocytopenia, as well as elevated Hb F and RBC
adenosine deaminase (ADA) in more than 85% of patients. In the bone marrow,
a pure erythroblastopenia without abnormalities in the other haematopoietic cell lines
is characteristic. The cumulative incidence for MDS, AML, and some solid tumours
(osteosarcoma, Hodgkin’s lymphoma) has been estimated at 20% at 46 years, which
implies an increased risk of developing cancer. The treatment is based on the response
of a large number of patients to steroids. However, it is advised not to perform this
treatment until after the first year of age. Until then, and in those patients who do not
respond to steroids, or who require them at very high doses, the only treatment will
be adequate transfusion support with packed red blood cells. The only curative
treatment for the disease is the HSCT, provided the existence of an identical HLA
family donor [11].
4.3 Congenital dyserythropoetic anaemia (CDA)
CDA is, in fact, a heterogeneous group of defects of erythropoiesis with medullary
abortion of the erythroblasts before maturing to reticulocytes (dyserythropoiesis), and
important erythrocyte morphology abnormalities. Clinically, CDA is characterized by
anaemia, usually macrocytic, and iron overload. To date, five clinical forms of CDA
have been described: CDA I, CDA II, CDA III, CDA IV and CDA with thrombocyto-
penia [17]. The first two (CDA I and CDA II) have an autosomal recessive hereditary
pattern and the other two (CDA III and CDA IV) are autosomal
dominant. Thrombocytopenia with CDA has an inheritance linked to the X chromo-
some. The two best known CDAs are CDA I (OMIM 224120) characterized by a
marked dyserythropoiesis and frequent inter nuclear chromatin bridges and CDA II
(OMIM 224100), characterized by marked dyserythropoiesis associated with erythro-
blastic binuclearity or multinuclearity, and the presence of erythroblasts with double
cell membrane (Figure 2). CDA III (OMIM 105600) is a ultra-rare disease where the
marked dyserythropoiesis is associated with severe nuclear size and chromatin mor-
phological abnormalities that resemble an erythroleukemia or Di-Guglielmo disease.
CDA I is due to mutations of the CDAN1 gene or less frequently to mutations
of the C15ORF41 gene, In a small percentage of cases the mutation is unknown.
DBS Subtypes % of patients Locus Mutated Gene Protein
AD <1 17p13.1 RPL26 RPL26
AD <1 17q12 RPL19 RPL19
AD <1 2q11.2 RPL31 RPL31
AD <1 8q12.1 RPS20 RPS20
AD <1 19p13.2 RPS28 RPS28
LX <1 Xp11.23 GATA-1 GATA1
Unkown 40 — — —
Source: [35].
Table 3.
Genetic subtypes and genes implicated in Diamond-Blackfan anaemia (DBA).
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In CDA II, the disease is due to mutations of the SEC23B gene and in CDA III, its
most frequent gene mutation is the KIF23 gene.
5. Rare Anaemias due to red blood cell defects
RBC defects can be classified into two main groups: (a) Hereditary or intrinsic
defects due to structural or functional abnormalities of RBC components
haemoglobin (haemoglobinopathies), membrane (membranopathies) and enzymes
of metabolism (enzymopathies), and (b) Acquired or extrinsic defects due to blood
plasma or vascular abnormalities. In both cases the consequence is a haemolytic
syndrome characterized by anaemia of variable severity associated with a compen-
satory increase of bone marrow erythropoiesis and of circulating reticulocytes. In
addition to anaemia, the haemolytic syndrome is characterized by three main clin-
ical manifestations 1. reticulocytosis, 2. splenomegaly and 3. jaundice [18].
5.1 Haemoglobinopathies
Haemoglobinopathies are the most frequent RBC defects in comparison with
membranopathies and erythroenzymopathies that in many cases can be considered
ultra-rare anaemias (prevalence <1 case per 106 inhabitants). All these diseases are
more frequent in Southern Europe than in Central or Northern Europe, and their
clinical expression is always an hereditary haemolytic anaemia [19, 20]. Haemoglo-
binopathies are the consequence of globin gene mutations that can alter the syn-
thesis (thalassaemias) or the structure of haemoglobin (structural
haemoglobinopathies). Its worldwide prevalence is around 269 million carriers, and
in Europe there are risk populations, especially for thalassemia, which are located in
the geographical regions surrounding the Mediterranean basin (Mediterranean
Anaemia).
The most frequent haemoglobinopathy is HbS (OMIM 603903), prevalent in
African populations due to the protection that it has offered against malaria. HbS is
the result of substitution of valine for glutamic acid in the sixth position of the
globin beta chain and in its homozygous form or combined with other haemoglobi-
nopathies, is responsible for sickle cell disease (SCD) that consists in haemolytic
anaemia associated with severe vaso-occlusive crises and pain due to multiple
micro-infarcts [21]. These crises are triggered by hypoxia that decreases HbS
Figure 2.
Typical bone marrow picture of Congenital Dyserythropoietic Anaemia type II also known by hereditary
erythroblastic multinuclearity with positive acidified serum lysis (HEMPAS) test.
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solubility leading to a characteristic RBC shape distortion (sickle cell) and to a
drastic decrease of deformability (Figure 3) Over the last 30 years, it has been
observed a significant increase due to the immigration impact of populations from
other geographical areas, mainly from Sub-Saharan African regions but also from
Asia and Central America, where this disease is very prevalent. Currently, the
neonatal screening programs allow an early diagnosis of the disease and its preven-
tive treatment from the first years of life and, as a consequence, the frequency of
complications have significantly reduced, and mortality during early childhood
dramatically decreased [22]. There is no specific treatment for SCD, although in
severe cases, the administration of hydroxyurea (HU) is recommended since, as the
concentration of HbF increases, the frequency of vaso-occlusive crises, the need for
transfusions, and especially the onset of the acute thoracic syndrome decrease. In
addition to HbS, there are other structural haemoglobinopathies of clinical interest
such as HbS, HbJ HbD and unstable haemoglobins that precipitate, and inclusion
bodies or Heinz bodies are formed (Figure 4). Clinically, they present with a
chronic haemolytic syndrome of variable severity and unlike the SCD, patients
presents an autosomal dominant pattern of inheritance.
Figure 3.
Sickle-cells in a SCD patient with vaso-occlusive crisis.
Figure 4.
Howell Jolly bodies in a patient with unstable haemoglobin.
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5.2 Thalassaemias
Thalasaemias are due to the decrease in the synthesis of a globin chain (alpha or
beta), due to absence, diminution or defective translation of specific messenger RNA
(mRNA) caused by deletions or point mutations of the globin genes. While point
mutations predominate in beta genes, large deletions are more frequent in alpha
genes. According to the type of mutation and the intensity of the synthesis decrease,
the severity of the clinical picture can bemore or less intense [23]. In beta thalassemia
the milder forms consist of a slight or moderate hypochromic andmicrocytic anaemia
(thalassemia trait) whereas the more severe clinical forms can be classified as “thal-
assemiamajor” or “thalassemia intermedia” depending on the severity of the anaemia
and the periodic transfusion requirements, respectively. In alpha thalassemia, as the
genetic cluster has two genes, the mutation of a single allele, relatively common in
Southern Europe in characterized by a moderate microcytosis (MCV around 80 fl)
without anaemia alpha thalassemia trait, whereas if more than one allele is affected
more severe forms of alpha-thalassemia occur The mutation of three alleles gives rise
to the so-called haemoglobinopathy H, a clinical form very similar to intermediate
beta thalassemia but with the presence of HbH or beta-globin tetramers, a result of
the excess or imbalance of beta chains due to the decrease of alpha chains. The
complete loss of the four alleles (homozygous alpha-thalassemia) is incompatible
with life (hydrops faetalis).
Diagnosis of both forms of thalassemia is based on the data provided by the CBC
and the study of haemoglobins by electrophoresis or high-performance liquid chro-
matography (HPLC). In the case of beta thalassemia trait an increase in the HbA2
fraction is always observed, whereas in alpha thalassaemia trait the haemoglobin
pattern is normal and a molecular study is mandatory. An accurate family study is
also very important to prevent diagnostic errors and the application of unnecessary
treatments. In addition, an appropriate identification of the carrier condition allows
the identification of couples at risk.
The treatment of severe clinical forms of β-thalassemias has been historically
based on blood transfusions and iron chelation therapy. The only curative therapy
currently available is allogeneic haematopoietic stem cell transplant (HSCT) from
suitable donors. However, with the limited pool of suitable donors, HSCT remains
unavailable for many thalassemic patients. They may instead benefit from globin
gene therapy and other modalities, which exploit recent advances in understanding
of globin gene regulation [24].
5.3 Membranopathies
Membranopathies are due to structural or functional defects of the RBC mem-
brane proteins. In general, they are inherited as autosomal dominant pattern but
transmitted with a recessive character. Hereditary spherocytosis (HS; OMIM
182870, 182,900, 270,970, 612,653, 612,690) is the most frequent cause of HHA in
Caucasians due to a defect of membrane skeletal proteins that cause vesiculation
and partial loss of the same with the decrease in surface/volume ratio and formation
of spherocytes (Figure 5). Proteins affected in HS are beta-Spectrin (SPTB-1)
Ankyrin and Band 3, and haemolysis occurs almost exclusively in the spleen, lead-
ing to frequent severe splenomegaly. Along with splenomegaly, several complica-
tions of HHA can be frequently observed in HS such as, intermittent jaundice and
increased bilirubin pigments leading to premature gallstone formation, transient
erythroblastopenia crisis due to parvovirus B19 infection, folic acid deficiency and
torpid malleolar ulcers [25]. In general, physicians become more familiar with
diagnosing HS in the newborn period, fewer neonates with HS will develop
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hazardous hyperbilirubinemia or present to emergency departments with unantici-
pated symptomatic anaemia. The early suspicion, prompt diagnosis and treatment,
using anticipatory guidance, will prevent adverse outcomes in neonates with
HS [26].
The diagnosis of HS is based on the triad: (1) anaemia with jaundice, (2) severe
splenomegaly and (3) spherocytosis, easily demonstrated by the peripheral blood
morphological examination (Figure 5). Currently the diagnosis of HS can be easily
performed by measuring RBC deformability and osmotic gradient ektacytometry
(OGE) using the new generation LoRRca Osmoscan from Mechatronics [27].
Curves obtained with this device allow a clear distinction between hereditary
spherocytosis and the other RBC hereditary membranopathies, elliptocytosis and
xerocytosis (Figure 6). The implementation of the automated haematological
analysers that determine the CCMH by means of a direct system, allows us to use
this magnitude as a criterion of HS when it is increased in the presence of an
elevated reticulocyte count. Finally, the use of the EMA-binding test technique is
currently being implemented as a reference technique, especially in the diagnosis of
HS, together with ektacytometry. This test is based on the measurement of the
fluorescence intensity in RBCs after incubation with a fluorochrome, eosin-5-
maleimide (EMA) that binds specifically to the anion transporter (Band 3) and
decreases when Band 3 decreases.
Another hereditary membranopathy is hereditary elliptocytosis (HE, OMIM
109270, 130,600, 179,650, 225,450, 611,804), with milder clinical expression when
compared to HS, but with the presence of more than 30% of circulating elliptocytes
in peripheral blood (Figure 7). Like HS, HE is due to a skeletal protein defect, mainly
alpha-Spectrin (SPTA-1) and Band 4.1 that alters the elasticity of the membrane
preventing its recovery after elongation [28]. There is no loss of membrane and,
therefore, CCMH is normal. OGE profile (Osmoscan) shows here a characteristic
curve that is different from HS (Figure 6). In severe clinical forms of HE known as
hereditary pyropoikilocytosis (HPP) the SPTA-1 gene mutation in heterozygous
state is associated “in trans” with a SPTA-1 “Lely”mutation leading to severe HHA
with markedly abnormal RBC morphology and decreased heat stability (Figure 8).
Finally, there is a very rare form of membrane disease called hereditary
stomatocytosis (OMIM 194380, 185,000) which most relevant characteristic is the
presence of RBC with an elongated central pallor instead of a round one (Figure 9).
Its genetic and molecular mechanism is poorly understood, although it is known
that in all forms there is a disorder of the permeability to sodium or potassium ions
by which the RBC can be hydrated or dehydrated. These disorders of erythrocyte
Figure 5.
Circulating peripheral blood spherocytes in a patient with hereditary spherocytosis.
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hydration are classified as primary, due to inherent disorders of erythrocyte volume
regulation, and secondary, due to other disorders affecting the erythrocyte that
secondarily influence cell hydration. In general, the degree of perturbation of water
and ion content parallels the degree of haemolytic anaemia [29].
Overhydrated stomatocytosis (OHSt) or hereditary hydrocytosis refers to a rare,
heterogeneous group of disorders with haemolytic anaemia and large numbers of
stomatocytes on peripheral blood smear (Figure 9). OHSt is associated with mark-
edly increased sodium permeability of the membrane from 10 to 40 times normal.
This leads to a significant increase in intracellular sodium with a lesser decrease in
intracellular potassium, resulting in increased total mono-valent cation content and
increased intracellular water. Erythrocyte membranes from many OHSt patients
Figure 6.
Osmotic gradient ektacytometry (OGE) profiles from Osmoscan (LoRRca) in different hereditary
membranopathies. EI: Elongation Index.
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lack stomatin, but mutations have not been found in the gene of affected patients
and erythrocytes from stomatin knockout mice are normal. There is a variant of
OHSt variant known as Cryohydrocytosis in which patient erythrocytes exhibit
minimal to mild changes in cation leak at physiologic temperatures, but a marked
increase in monovalent cation permeability at low temperature, typically 5°C.
Erythrocytes demonstrate a sphero-stomatocytic morphology on peripheral smear.
Heterozygous missense mutations in band 3, the anion exchanger (SLC4A1), have
been identified in some cryohydrocytosis patients [29]. Dehydrated stomatocytosis
or hereditary xerocytosis (HX) syndromes, are the most common primary disorders
of erythrocyte hydration and are the most clinically heterogeneous. HX erythro-
cytes are dehydrated due to a cation leak, primarily of potassium, that leads to
decreased potassium concentration. Because the cation leak is not accompanied by a
proportional net gain of sodium and water, cellular dehydration ensues. Peripheral
blood smear reveals few target cells, and occasional dessicytes (erythrocytes with
haemoglobin puddled to one side), and rare stomatocytes. MCHC is increased
(34–38 g/dL), and RBC osmotic fragility is decreased, both reflecting cellular dehy-
dration [30]. Osmotic gradient ektacytometry (LoRRca Osmoscan) reflects a char-
acteristic pattern of mixed reduced deformability index and dehydration given by a
leftward shift of the minimal osmolality point (Figure 6).
When studied at the genetic level, in most cases of HX, mutations in PIEZO1
have been identified. PIEZO proteins are ion channels mediating mechanic sensory
transduction in mammalian cells, and PIEZO1 is a large integral membrane protein
Figure 8.
Peripheral blood MGG stained examination of a newborn with hereditary pyropoikylocytosis (HPP).
Figure 7.
Ellyptocytes in a patient with hereditary elliptocytosis.
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with numerous transmembrane domains that assemble into a homo-multimeric
complex fully active as a mechanic sensitive cation channel [29]. A few HX patients
do not have mutations in PIEZO1, but instead have mutations in the Gardos chan-
nel, encoded by KCNN4. The role of Gardos channel in normal erythrocytes has not
yet been defined, butin HX-associated mutant KCNN4 channels demonstrate alter-
ations in channel kinetics and trafficking. Clinically, HX patients with KCNN4
mutations experience variable degree of anaemia and RBC dehydration with typi-
cally more severe forms than in PIEZO1-mutant HX patients [29].
Treatment of HHA due to RBC membrane defects are always palliative,
depending on the severity of anaemia. In HS, splenectomy allows a complete
recover of haemoglobin concentration, whereas in the HE this recovery is only
partial. In HS, splenectomy is not recommended because it facilitates thrombotic
events due to an increased thrombophilia.
5.4 Erythroenzymopathies
Erythroenzymopathies are hereditary diseases due to a defect of RBC metabo-
lism, in general an enzyme deficiency, that can be associated with an haemolytic
crisis, a chronic haemolytic anaemia (HHA), neonatal cyanosis with metahaemo-
globinemia or c) hereditary erythrocytosis. An association between enzymatic
defect and HHA has been described in 14 of the 38 enzymes that make up the
erythrocyte metabolism (Table 4). Some enzymatic defects produce haemolysis
only under cellular stress produced by infections, oxidizing drugs or by the intake of
fava beans. Other enzymatic deficiencies are associated with chronic non-
spherocytic haemolytic anaemia (CNSHA). On some occasions, the expression of
the deficiency is not restricted to the erythrocyte, but extends to other tissues,
mainly the neurological, hepatic or muscular tissues, and a neuropathy,
hepatopathy or myopathy, respectively, associated with anaemia appears. The RBC
is especially sensible to enzymopathies because, unlike other cells, it cannot
resynthesize the deficient enzymes because it lacks a nucleus and ribosomes. Enzy-
matic deficiencies occur when one of the enzymes of the reduced RBC metabolism
is unstable and disappears very quickly, or has lost catalytic functionality and lacks
activity. In the mature RBC there are two fundamental metabolic pathways: (1) the
anaerobic glycolysis, by which glucose is used to generate ATP and (2) the aerobic
pentose phosphate pathway (PPP), by which it eliminates any oxidative aggression
to generate NADH and NADPH (Figure 10). ATP is used to meet energy require-
ments and NADH to reduce methaemoglobin. The NADPH is used to reduce the
oxidized glutathione (GSH) which, in turn, is required to maintain the sulfhydryl
groups of proteins in a reduced state and to detoxify hydrogen peroxide
Figure 9.
Typical RBC morphology in a patient with hereditary stomatocytosis.
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(Figure 11). Enzymopathies have been described in both metabolic pathways.
Glucose-6-phosphate dehydrogenase (G6PD, OMIM 300908, 134,700) is the most
frequent antioxidant system, and shows hereditary transmission linked to sex. It is
especially frequent in Africa, Asia and in the Mediterranean region (Greece and
Italy, mainly) and, due to its polymorphic nature, it has many variants, among which
the G6PD A-, predominant in black people, and the G6PD () Mediterranean, pre-
dominant in Caucasians. In G6PD A-forms, the enzyme is unstable but enzymatic
activity is almost normal in reticulocytes, whereas in Mediterranean G6PD variants,
the enzyme is even more unstable, and its activity is very low even in reticulocytes.
This explains that in G6PD A-carriers, the acute haemolytic episode is self-limited and
the recovery of the anaemia is faster than in the carriers of Mediterranean G6PD
variants. Clinically, the G6PD deficiency occurs with haemolytic crisis sometimes
associated with severe anaemia, in general triggered by the intake of oxidant sub-
stances, like fava beans (favism), or certain oxidizing drugs. Due to this, the carriers of
a G6PD deficiency can remain asymptomatic for many years, until a contact occurs
with the substances that may trigger the haemolytic crisis. Among the drugs that can
induce haemolysis in G6PD deficiency, can be mentioned certain analgesics,
sulphonamides, antimalarials, and antibiotics [31]. Favism, a severe haemolytic anae-
mia induced by fava beans ingestion or exposure to pollen from the plant, is the most
frequent clinical manifestation in caucasians bearing the deficient G6PDMediterra-
nean variant, but also the G6PD A () variant (G66PD Betica). There are also ultra-
rare forms of G6PD deficiency that do not obey to polymorphic variants but to
Enzyme deficiency Prevalence Inheritance Haemolysis Comments
Hexokinase (HK) Ultra-rare Recessive Yes (+++) Low 2,3DPG level, poor tolerance of
anaemia, 20 cases described.
Glucose phosphate
isomerase (GPI)
Very rare Recessive Yes (++) 45 cases, 24 mutations re- ported;
deficiency extended to leucocytes
and platelets
Phosphofructokinase
(PFK)
Very rare Recessive Variable 35 reported cases; variable degree of
haemolysis and myopathy
Aldolase (ALD) Ultra-rare Recessive Yes 3 cases reported
Triosephosphate
isomerase (TPI)
Very rare Recessive Yes Severe generalized disorder;
widespread tissue involvement;
neurologic, infectious and cardiac
complications, 12 mutations
described
Phosphoglycerate
kinase (PGK)
Ultra-rare X-linked Yes, usually Mental retardation and neurologic
disturbances in hemizygous men;
specific amino acid substitutions
identified in 7 variants
Enolase (ENOL) Ultra-rare Dominant Yes 3 cases described
Pyruvate kinase (PK) The most
common
glycolytic
defect
Recessive Yes First described and best studied
defect, prototype for the
group. 1:20,000 affected in the
general population, 180 mutations
described
Lactate
dehydrogenase
(LDH)
Ultra-rare Recessive No 7 cases described, myopathy with
lack of M-subunit
Table 4.
Erythroenzymopathies of the glycolytic pathway.
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sporadic variants that present with a chronic haemolytic syndrome (CSSHA). Other
factors that can induce haemolysis in the G6PD deficiency are viral infections, espe-
cially influenza and hepatitis, diabetic ketoacidosis, and other different situations
called of “stress.” The diagnosis of G6PD deficiency is based on the clinical history, and
the exclusion of the autoimmune mechanism through the negativity of the direct
antiglobulin test (DAGT) or Coombs test. During the haemolytic crisis, the observa-
tion of the smear shows the presence of eccentrocytes or RBCs subjected to oxidative
stress where haemoglobin is pushed off to one part of the cytoplasm (Figure 12).
For screening purposes, the fluorescent spot test is used based on demonstrating the
formation of NADPH (fluorescent) from NADP (non-fluorescent) in the Beutler’s
G6PD fluorescence spot test or the reduction of methaemoglobin in the presence of
methylene blue.
Figure 10.
Anaerobic glycolysis and antioxidant metabolic pathways of red blood cells. Abbreviations: BPG,
bisphosphoglyceric acid; DHAP, dihydroxyacetone phosphate; F6P, fructose 6-phosphate; FDP, fructose-1,6-
diphosphate; G3P, glycerol 3-phosphate; G3PD, glyceraldehyde 3-phosphate dehydrogenase; G6P, glucose 6-
phosphate; G6PD, glucose-6-phosphate dehydrogenase; GCS, glutamylcysteine synthetase; GPI, glucose-
phosphate isomerase; GS, glutathione synthetase; GSH, glutathione; GSSG, glutathione disulfide; HK,
hexokinase; LD, lactate dehydrogenase; NADP, nicotinamide adenine dinucleotide phosphate; PEP,
phosphoenolpyruvic acid; PFK, phosphofructokinase; PG, phosphoglyceric acid; PGK, phosphoglycerate kinase;
PK, pyruvate kinase; Ru5P, ribose-5-phosphate isomerase.
Figure 11.
Anti-oxidant system present in RBC to protect the cells against the oxidant threat generated by the ingestion of
oxidant drugs of fava beans (favism).
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The pyruvate kinase deficiency (PKD, OMIM 266200) is the most frequent
enzyme of anaerobic glycolysis (Embden-Meyerhof pathway) and the most fre-
quent cause of hereditary haemolytic anaemia (HHA), after hereditary
spherocytosis [32]. It is an enzymopathy much less frequent than G6PD deficiency
and its diagnosis requires the quantification of enzymatic activity in patient’s
haemolysates. Since haemolytic anaemia in PK deficiency is always due to mutations
in the PKLR gene, leukocytes have a normal PK activity, so if they are not eliminated
well when preparing the haemolysate, they can geopardise the result and mask the
existence of a RBC PK deficiency (PKD). To avoid this important cause of error
(false negatives), blood treated with anticoagulant must be filtered through a col-
umn of celulose-micro celulose in order to eliminate leukocytes and platelets. Also
the presence of a high number of circulating reticulocytes, very frequent in new-
borns and children, can also give false negatives because the PK activity of the
reticulocytes is much higher than that of the mature RBCs. Therefore, if in the
presence of intense reticulocytosis a normal PK activity is obtained, the result should
be confirmed by determining the quotient between PK activity and hexokinase
(HK). HK is an enzyme whose activity also increases in the presence of
reticulocytosis and, therefore, if this increase is much greater than that of PK, this
enzyme deficiency is evidenced by a significant decrease in the PK / HK ratio [33].
Very recently a concise guide to PK deficiency for primary care providers, but
also for haematologists, healthcare providers and medical students has been
published [34]. There, the underlying PKD defect is explained in great detail
together with its mode of inheritance, clinical manifestations, diagnostic procedures
and an attempt for medical treatment.
6. Databases and epidemiology
Clinical epidemiology, originally confined to the global problems of infectious
diseases, became, in the last 50 years, the fundament of today’s evidence based
medicine. No medical stakeholder is able to oversee the abundance of data describ-
ing prevalence, incidence, clinical patterns and health risks from all regions in the
world. The majority of studies are concerned with common diseases, but there is
still a paucity of data for rare diseases, which came in the scope of medical stake-
holders in the last decade.
In RA, as in other rare and very rare disorders, only supranational networks can
provide valid data. ENERCA has concentrated on data from the MS of the EU on a
Figure 12.
Excentrocytes present in the blood of a patient with G6PD deficiency and haemolytic crisis.
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subset of RA. However, it is often overlooked that social-economic conditions and
medical practices are different in the different MS, resulting in different recognition
of the epidemiological data studied [20]. Frequency is a general term to compare
differences between the occurrence of a given disease, in the case of rare anaemias
between populations defined by geographic regions or populations of different
origin (such as the formerly called races) in a given region. The latter became of
paramount importance with the ongoing immigration of people from the Mediter-
ranean basin to North- and Middle Europe and from Asia and Africa to all MS, as
mentioned above. The frequency is a useful parameter in any first approach of
disease characteristics and a useful tool to decide on the methodology to estimate
more precise issues. No one would challenge the fact, that thalassemia is much more
frequent in the Mediterranean area or in immigrants within the Northern European
countries. However, mathematically defined parameters are needed for research
and health care planning. Prevalence, or more exactly prevalence proportion, is the
main indicator used for any epidemiological studies in congenital diseases,
representing the vast majority of conditions considered in disease category. Parox-
ysmal Nocturnal Haemoglobinuria (PNH) is an exception, with prevalence being of
major significance, alike for the situation of cancers. For very rare anaemias
included in ENERCA, usually period prevalence is measured, using a defined num-
ber of observation years rather than an index day as used for the so called point
prevalence in common diseases. Another useful measure is the number of affected
children of all live births in a given observation period; in this case, the period of
definition of live birth (e. g. Days after birth) should be indicated, to avoid bias due
to early mortality. An effective instrument to measure true prevalence a proportion
is obtained with post-natal screening programs, as described for SCD. Ideally, all
cases of a given disease or disease category in a population at time should represent
the “true” prevalence. However, in the case of rare anaemias, the detection rate
(number of detected/number of existing cases) is often less than 1. As shown by the
work of ENERCA, there are strong indicators that the detection rates in the MS vary
considerably depending on socio-economic conditions, and the same is true for the
proportion of misclassifications. These data are of importance for any attempt to
harmonize the diagnosis of rare anaemias in the European countries.
An inherent, unsolved problem of all registries is sustainability. Time trends, so
important considering the influence of scientific as well as population changes due
to both demographic evolution and migration can only be ascertained if sustain-
ability can be guaranteed by resources of much longer duration than available
today. Clinical trials, even though primarily directed to progress of therapeutic
measures and often dependent on industrial interests are another source of epide-
miological data. We hope that final EuorBloodNet standardization will provide
solutions to many of these problems.
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